Sign in
Taking peoplePhase 3

Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis

Key facts

Who runs it
Laboratorios Ojer Pharma S.L.
Where
Poland10 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
200 people, planned
Started
15 Jan 2025
Planned end
21 Oct 2026
Type of study
Interventional
Record updated
19 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Participants must have at least 3 recurrences or herpes labialis within the past year
  • At least half of the recurrences are preceded by recognizable prodromal symptoms, e.g., itching, redness, burning, tingling or a sense of irritation
  • At least half of the prodromes are followed by classical lesions, e.g., ulcer, vesicle, and/or hard crust
  • Age ≥18 years at the time of signing the informed consent form
  • Able to read, understand, and sign the informed consent document
  • Able to understand and follow the study procedures, including completing the study diary

Who cannot take part

  • Alcohol or drug abuse
  • Simultaneous participation in another clinical trial or participation in any clinical trial involving an Investigational medicinal product within 30 days prior to written informed consent for this trial
  • Subjects who have previously enrolled in this study
  • Immunocompromised patients or patients receiving immunosuppressive therapy
  • Systemic, severe as well as history of uncontrolled chronic disease or a concurrent clinically significant illness, or medical condition, which in the investigator’s opinion, wouldcontraindicate study participation or compliance with protocol -mandated procedures
  • Medical or dermatological conditions that interfere with the treatment or assessment of the herpes lesions (e.g., eczema, psoriasis, acne, seborrhoeic dermatitis)
  • Known hypersensitivity/allergic reaction to the study drug substance or any of the formulations’ excipients
  • Known hypersensitivity to valaciclovir
  • History of herpes keratitis
  • History of unresponsiveness to acyclovir therapy
  • Participant who is unable or is not expected to reliably comprehend or satisfactorily assess a herpetic lesion
  • Unlikely to co-operate with the requirements of the study
  • Females who are pregnant, breastfeeding, or planning a pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of Lipovir® Gel compared to Zovirax® Cream on patients with RHL

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Multicenter, randomised, open-label with blind evaluation active and placebo-controlled, non-inferiority clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) on patients with Recurrent Herpes Labialis
Record updated
19 October 2026